Skip to content

Comparison of oral isotretinoin combined with prednisone and doxycycline sequential isotretinoin in the treatment of moderate to severe acne

Comparison of oral isotretinoin combined with prednisone and doxycycline sequential isotretinoin in the treatment of moderate to severe acne

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102102
Enrollment
Unknown
Registered
2025-05-08
Start date
2024-01-13
Completion date
Unknown
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to severe acne with the following symptoms: Acne is obvious, including numerous pimples, inflammatory papules, or pustules

Interventions

Treatment group:Prednisone is reduced within 4 weeks with oral isotretinoin softgels (10 mg to 20 mg) plus low-dose prednisone tablets (10 mg to 20 mg) depending on resolution of inflammatory rash.
Positive control group:Oral doxycycline 100mg-200mg is administered sequentially over 4 weeks with oral isotretinoin (10mg-20mg).

Sponsors

Qingxian People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the diagnostic criteria for moderate or severe acne vulgaris; 2. Aged between 16 and 45 years old, no history of serious medical diseases, mental illnesses and severe malignant skin tumors, and female patients are not in the stage of trying to conceive, pregnant or breastfeeding; 3. Those who have not received oral and topical treatment for acne within 1 month, or who have received treatment but the effect is not obvious; 4. Comply with the treatment plan, be able to have regular follow-up visits, cooperate with the collection of photos before and after treatment, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients who are pregnant or trying to be pregnant ; 2.Explosive acne and acne-like rash; 3.Serious infection and liver and kidney function injury indicated by blood routine; 4.Mental abnormality ? oral drug allergy or intolerance; 5.Other reasons could not complete the clinical study.

Design outcomes

Primary

MeasureTime frame
Skin symptom grading score;

Countries

China

Contacts

Public ContactZhang Luo

Qingxian People's Hospital

491972572@qq.com+86 317 4313048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026